ストックスクリーナーアプリを入手
25.18
2.14%
-0.55
アフターアワーズ：
25.00
-0.18
-0.71%
前日終値:
$25.73
開ける：
$25.8
24時間の取引高:
1.82M
Relative Volume:
0.92
時価総額：
$4.16B
収益：
-
当期純損益:
$-451.71M
株価収益率:
-7.8051
EPS:
-3.2261
ネットキャッシュフロー:
$-462.19M
1週間 パフォーマンス:
+3.03%
1か月 パフォーマンス:
+13.37%
6か月 パフォーマンス:
+40.75%
1年 パフォーマンス:
+155.63%
1日の値動き範囲:
$24.41
$25.99
1週間の範囲:
$23.95
$26.26
52週間の値動き範囲:
$9.57
$26.26
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
25.18 | 4.24B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy - Investing News Network
Dyne Therapeutics receives FDA clearance for FSHD trial - Investing.com
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) - marketscreener.com
Dyne Targets FSHD, a Muscle Disease With No Approved Therapies - Stock Titan
Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dyne Therapeutics stock hits 52-week high at 25.06 USD By Investing.com - Investing.com UK
ForDyne B.V. (DYN) files Rule 144 to potentially sell 261,460 common shares - Stock Titan
Dyne Therapeutics stock hits 52-week high at 25.06 USD - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Inc (DYN) Cash Flow - TradingKey
Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering - Pulse 2.0
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
TradingKey - TradingKey
Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Dyne Therapeutics Grants New Hires Options on Up to 358,600 Shares - Stock Titan
Dyne Therapeutics grants inducement equity awards for 475,100 shares to 12 new hires - Bitget
DYN Initiated Coverage On by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus
Dyne Therapeutics closes $431.4 million stock offering By Investing.com - Investing.com South Africa
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway - The Globe and Mail
Dyne Therapeutics closes $431.4 million stock offering - Investing.com
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Sells 21M Shares at $20.50 in Offering - Stock Titan
Dyne a new overweight at Cantor on platform for neuromuscular disorders - Seeking Alpha
DYN: Dyne Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? - Yahoo Finance
Dyne Therapeutics closes upsized public offering of 21,045,000 shares at $20.5 each - Bitget
Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa
Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com
Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - MSN
Why Dyne Therapeutics (DYN) Stock Is Down Today - Moomoo
Dyne Therapeutics (DYN) Upsizes Public Offering to $375.15M Amid Stock Decline - GuruFocus
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Why is Dyne Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Canada
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):